Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-VAV2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VAV2 also known as Vav 2 guanine nucleotide exchange factor is a member of the VAV family of proteins which function as guanine nucleotide exchange factors (GEFs). It has a molecular mass of approximately 100 kDa. The protein converts inactive GDP-bound Rho family GTPases such as Rac1 and Cdc42 into their active GTP-bound form. VAV2 is expressed in various tissues including the brain heart and lung indicating its broad role in cellular signaling across different systems.
Biological function summary
VAV2 influences multiple cellular processes through its role as a GEF. This protein does not form a part of a static complex but interacts dynamically with other signaling components. VAV2 regulates cytoskeleton organization cell migration and growth by activating Rho family GTPases. Its activity impacts processes such as neuronal development and immune response by modifying the actin cytoskeleton which is important for cell movement and morphological changes.
Pathways
VAV2 plays an integral role in signaling cascades like the Ras and MAPK pathways. It interacts closely with proteins like Rac1 and Cdc42 to propagate signals that influence cell proliferation and survival. By facilitating the switch from inactive GDP-bound states to active GTP-bound forms of Rho GTPases VAV2 integrates signals from cell surface receptors to downstream effectors that mediate cellular responses to external stimuli.
VAV2’s function connects to cancer progression and cardiovascular disorders. Changes in VAV2 expression or activity can lead to abnormal cell growth and differentiation linking it to cancerous transformations. Additionally because VAV2 modulates cell migration and cytoskeletal dynamics its malfunction can contribute to cardiovascular diseases by affecting vascular smooth muscle cells and endothelial cells. In both contexts VAV2's interactions with Rho family proteins like Rac1 highlights its influence in disease mechanisms.
